EP2968328A4 - Compositions for use in treating eye disorders using dipyridamole - Google Patents

Compositions for use in treating eye disorders using dipyridamole

Info

Publication number
EP2968328A4
EP2968328A4 EP14764673.1A EP14764673A EP2968328A4 EP 2968328 A4 EP2968328 A4 EP 2968328A4 EP 14764673 A EP14764673 A EP 14764673A EP 2968328 A4 EP2968328 A4 EP 2968328A4
Authority
EP
European Patent Office
Prior art keywords
dipyridamole
compositions
eye disorders
treating eye
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14764673.1A
Other languages
German (de)
French (fr)
Other versions
EP2968328A1 (en
Inventor
Moshe Rogosnitzky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Od Ocular Discovery
Original Assignee
REMEDEYE Inc
REMEDEYE Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by REMEDEYE Inc, REMEDEYE Inc filed Critical REMEDEYE Inc
Publication of EP2968328A1 publication Critical patent/EP2968328A1/en
Publication of EP2968328A4 publication Critical patent/EP2968328A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
EP14764673.1A 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole Withdrawn EP2968328A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL225179A IL225179A (en) 2013-03-12 2013-03-12 Compositions for use in treating eye disorders using dipyridamole
PCT/IB2014/059645 WO2014141079A1 (en) 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole

Publications (2)

Publication Number Publication Date
EP2968328A1 EP2968328A1 (en) 2016-01-20
EP2968328A4 true EP2968328A4 (en) 2016-11-23

Family

ID=48916407

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14764673.1A Withdrawn EP2968328A4 (en) 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole

Country Status (14)

Country Link
EP (1) EP2968328A4 (en)
JP (1) JP6820658B2 (en)
KR (2) KR20210010638A (en)
CN (1) CN105188702B (en)
AU (1) AU2014229371B2 (en)
BR (1) BR112015022084A2 (en)
CA (1) CA2905594A1 (en)
CL (1) CL2015002627A1 (en)
EA (1) EA035966B1 (en)
IL (1) IL225179A (en)
MX (1) MX2015012716A (en)
MY (1) MY182591A (en)
SG (2) SG11201507092QA (en)
WO (1) WO2014141079A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115282152A (en) * 2015-01-28 2022-11-04 瑞采生技有限公司 Compounds for enhancing PPAR γ expression and nuclear translocation and medical uses thereof
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
WO2021001805A1 (en) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations and their methods of preparation
WO2021001806A1 (en) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations with reduced impurities

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672417A1 (en) * 1994-03-17 1995-09-20 Rohto Pharmaceutical Co., Ltd. Reduction of elevated intraocular pressure
WO2010056710A1 (en) * 2008-11-11 2010-05-20 Biovista, Inc. Compositions and methods for treating eye diseases
EP2218442A1 (en) * 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP2363126A1 (en) * 2010-03-04 2011-09-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition comprising as active ingredient L-carnitine in combination with hydroxykynurenine-O-beta-DL-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672417A1 (en) * 1994-03-17 1995-09-20 Rohto Pharmaceutical Co., Ltd. Reduction of elevated intraocular pressure
EP2218442A1 (en) * 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
WO2010056710A1 (en) * 2008-11-11 2010-05-20 Biovista, Inc. Compositions and methods for treating eye diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BETH H. CARLOCK ET AL: "Pterygium: Nonsurgical Treatment Using Topical Dipyridamole - A Case Report", CASE REPORTS IN OPHTHALMOLOGY, vol. 5, no. 1, 25 March 2014 (2014-03-25), pages 98 - 103, XP055311925, DOI: 10.1159/000362113 *
MOSHE ROGOSNITZKY ET AL: "Ocular Applications of Dipyridamole: A Review of Indications and Routes of Administration", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS., vol. 32, no. 2, 1 March 2016 (2016-03-01), US, pages 83 - 89, XP055311924, ISSN: 1080-7683, DOI: 10.1089/jop.2015.0128 *
See also references of WO2014141079A1 *

Also Published As

Publication number Publication date
EP2968328A1 (en) 2016-01-20
JP6820658B2 (en) 2021-01-27
CL2015002627A1 (en) 2016-03-11
CN105188702A (en) 2015-12-23
AU2014229371B2 (en) 2018-05-10
AU2014229371A1 (en) 2015-10-29
BR112015022084A2 (en) 2017-07-18
SG10201706937UA (en) 2017-09-28
IL225179A0 (en) 2013-06-27
MX2015012716A (en) 2016-07-06
EA035966B1 (en) 2020-09-07
MY182591A (en) 2021-01-26
JP2016514123A (en) 2016-05-19
CA2905594A1 (en) 2014-09-18
KR20210010638A (en) 2021-01-27
IL225179A (en) 2017-01-31
KR20150126021A (en) 2015-11-10
EA201591653A1 (en) 2017-05-31
WO2014141079A1 (en) 2014-09-18
CN105188702B (en) 2019-03-26
SG11201507092QA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
HK1252978A1 (en) Compounds for use in treating neuromuscular disorders
HK1225305A1 (en) Methods and compositions for treating brain diseases
PT3811943T (en) Compound for use in the treatment of ocular disorders
HK1203830A1 (en) Compositions and methods for treating metabolic disorders
PL3882250T3 (en) Tetrahydropyranyl amino-pyrrolopyrimidinone for use in treating btk-mediated disorders
HK1217650A1 (en) Compositions and methods for treating severe pain
EP2989123A4 (en) Methods and compositions for treating bleeding disorders
PL3041831T3 (en) Alpha-tea salt forms: compositions and uses for treating disease
SG11201510300RA (en) Compositions and methods for treating skin
EP2968452A4 (en) Compositions and methods for treating retinal disease
IL242584B (en) Immunogenic composition for use in therapy
SG11201507092QA (en) Compositions for use in treating eye disorders using dipyridamole
EP2978452A4 (en) Compositions and methods for treating osteolytic bone disorders
GB201308753D0 (en) Compounds and their use in therapy
IL238363A0 (en) Methods for treating eye disorders
SI2815740T1 (en) Ophthalmic composition
ZA201508585B (en) Immunogenic composition for use in therapy
GB201304675D0 (en) Novel compositions having use in therapy
GB201314623D0 (en) Novel mucinase for use in therapy or prophylaxis
GB201223371D0 (en) Novel mucinase for use in therapy or prophylaxis
GB201308217D0 (en) Compounds and their use in therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151009

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20161026

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/519 20060101AFI20161020BHEP

Ipc: A61K 9/00 20060101ALI20161020BHEP

Ipc: A61P 27/02 20060101ALI20161020BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: O.D. OCULAR DISCOVERY

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20181008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221001